Case Report

Ultra-Low-Dose Radiotherapy for Palliation of Mycosis Fungoides

İpek Pınar Aral,¹ Neşe Göçer Gürok,² Aykut Oğuz Konuk,³ and Özlem Üçer⁴

¹Nevşehir Public Hospital, Radiation Oncology Department, Göreme, Turkey
²Elazığ Fethi Şekin City Hospital, Dermatology Department, Elazığ, Turkey
³Elazığ Fethi Şekin City Hospital, Radiation Oncology Department, Elazığ, Turkey
⁴Fırat University, Pathology Department, Elazığ, Turkey

Correspondence should be addressed to İpek Pınar Aral; ipekpt@hotmail.com

Received 18 November 2019; Accepted 28 February 2020; Published 24 March 2020

Copyright © 2020 İpek Pınar Aral et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction. Mycosis fungoides (MF) is a form of primary cutaneous T-cell lymphomas, and radiotherapy (RT) has been used to treat localized/limited lesions of MF. In this case report, the results of low-dose RT applied for palliative purpose are shared. Case Report. A 70-year-old male patient was admitted to the outpatient clinic 7 months ago with a generalized itchy rash. The result of the biopsy was reported as mycosis fungoides. Systemic treatment was not performed due to comorbid diseases (coronary Artery disease (CAD), chronic obstructive pulmonary disease (COPD), paraplegia due to stroke, and hypertension (HT)). The patient died due to multiorgan failure 2 months later, and no recurrence was observed. Conclusion. The palliation was achieved in the advanced MF patient with fractionated 6 Gy hemibody RT for the remaining 2 months of life.

1. Introduction

Mycosis fungoides (MF) is the most common form of primary cutaneous T-cell lymphomas [1]. Radiotherapy (RT) has been used to treat localized/limited lesions of MF since 1902. However, large-area skin irradiations using low-energy X-rays or electrons cannot be applied frequently due to equipment, experience, and technical deficiencies [2]. Total skin electron irradiation (TSEI) or total skin irradiation that uses photons (TSI) is performed in a limited number of experienced clinics, especially in MF patients with extensive involvement [3]. TSEI is a method used in the treatment of several dermatological malignant diseases, not only in MF but also in Sézary syndrome or Kaposi’s sarcoma; successful results were seen [3–5]. Despite the successful results of RT, the clinician’s awareness of this treatment remains low because of concern about side effects [4, 5]. In this case report, the results of ultra-low-dose RT applied for palliative purpose are shared.

2. The Case Report

A 70-year-old male patient was admitted to the outpatient clinic 7 months ago with a generalized itchy rash. A punch biopsy was taken from the thigh region in Fırat University Hospital. Epidermis showed significant spongiosis and mild irregular acanthosis. Also, lymphocytes and infrequent neutrophil infiltration were observed in the epidermis. Significant vacuolization was observed in the basal layer. Lymphocytes with irregular hyperchromatic nuclei were detected in the basal layer. Inflammation of mixed cells in the superficial dermis has been reported. Immunohistochemical staining was performed, or CD3, CD4, and CD8 staining was observed. The result of the biopsy was reported as mycosis fungoides. Systemic treatment was not performed due to comorbid diseases. The hemibody RT was applied. 2 Gy was given per fraction, with a total dose of 6 Gy. The significant clinical relief was observed with 6 Gy RT. The patient died due to multiorgan failure 2 months later, and no recurrence was observed. Conclusion. The palliation was achieved in the advanced MF patient with fractionated 6 Gy hemibody RT for the remaining 2 months of life.
treatment, which was administered before RT, improved the patient’s complaints of pruritus and hypothermia. The most complained areas of the patient were bilateral flexor and the upper anterior hemibody. RT was started on the flexor part of the bilateral arms with the most complaints. RT was applied with Elekta Versa HD device, SSD 100 cm, 6 MeV electron energy, 0 gantry angle, using a 20 × 20 applicator. The fraction (frc) dose was 2 Gy, and a total dose of 6 Gy was given. Clinical relief was observed after the first treatment (Figure 2). Following the response, RT was planned for the upper anterior hemibody (Figure 3). Because of the large RT area, right and left dual center radiotherapy was applied. For the right upper anterior hemibody radiotherapy, a 3200 gantry angle of 6 MeV electron energy with an SSD of 100 cm was used. Also, for the left upper hemibody radiotherapy, a 25 × 25 applicator at a 400 gantry angle with the same energy at SSD 100 cm was used. The 2 Gy was given per fraction, and the upper anterior hemibody received a total dose of 6 Gy. Significant clinical relief was observed with 6 Gy radiotherapy and medical treatment recommended by a dermatologist (Figure 4). The patient died due to multiorgan failure 2 months later, and no recurrence was observed in the RT areas.

3. Discussion

TSEI and TSI are technically difficult for patients with cutaneous lymphomas. Numerous approaches have been developed to solve “field problems” associated with such a large treatment volume. There is no “ideal” or even standard treatment for extensive skin irradiation. The current recommendations and treatment guidelines suggest several possible options for treatment [4].

Radiotherapy has been used for many years for patients with MF. Radiotherapy is not only effective treatment for the early-stage disease but also contributes to palliative treatment when the disease is advanced. For advanced MF, TSEI is involved in palliation of symptoms such as itching, pain, or dandruff. To date, experiences have shown that the effective dose of RT in the curative treatment of MF is 30 Gy or higher [5, 6]. In the literature, 20–30 Gy/10 frc or 8 Gy/1 frc treatments have been applied for palliative purposes. In advanced MF, the remission of symptoms has been reported in 36–96% of these treatments [6, 7]. Despite the promising
results, an important reason why TSEI is not frequently applied in clinical practice is the concern of acute and late side effects [8]. Acute side effects are erythema, edema, hyperpigmentation, and fatigue. Additionally, an increase in the risk of superinfection can be observed [9, 10]. The acute reaction occurs intensely in the second week of treatment. These symptoms are temporary and usually resolve within 2–3 weeks of treatment. Hospitalization may be required according to the prevalence of symptoms [11, 12]. Hyperkeratosis, hyper- and de-pigmentation, and hypohidrosis caused by sweat gland atrophy are late side effects that can be observed due to RT [10]. In our case, no acute side effects were observed.

Historically, total doses of 30 Gy and above were administered. Although the treatment results were successful, severe skin side effects were especially observed. Therefore, low-dose RT started to be tried after 2010 [13–15]. Kroeger et al. achieved adequate treatment results with fewer grade 2 skin toxicities with low-dose (12 Gy) TSEI compared to conventional doses [16]. Additionally, the low total dose is important in terms of the need for a second treatment and improved quality of life [17, 18]. Today, for TSEI, a total dose of 12–36 Gy is often preferred as 4–6 Gy per week, and complete response rates are 90% and above some series [19–21]. After the effectiveness of low dose, phase 2 studies for ultra-low- dose have been tried and ongoing [22].

There is no standard dose and administration schedule of low-dose and ultra-low-dose TSEI for palliative purposes. Since studies on low-dose TSEI are not common in the literature, treatment standards are limited. Besides, there is currently no randomized trial comparing low- and high-dose TSEI. In a study conducted in Copenhagen Dermatology Department, it was reported that 4 Gy low-dose TSEI given in 4 fractions caused partial remission in IB-II MF, but the remission was short-term [9, 23]. In the study of Funk et al., TSEI was applied with doses of 29 Gy and above, and complete remission was observed in 50% of the patients and the remission was permanent for 1–18 months [10]. In our patient, the response was obtained at ultra-low dose (6 Gy), so treatment was terminated, and the patient was followed up closely. In case of recurrence, a second treatment was planned. However, the patient developed cystitis 2 months after the end of treatment and did not improve despite medical treatment. Then, he died of a sudden deterioration of multiple organ failure. No complaints were observed in the RT area during this period. Our case is one of the lowest dose-fractionated palliative wide-field irradiations in the literature.

4. Conclusion

In this case evaluation, full palliation was achieved in the advanced MF patient with fractionated 6 Gy hemibody RT for the remaining 2 months of life.

Ethical Approval

The next of kin/guardians have consented to the submission of these case reports to the journal.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] K. Olek-Hrab and W. Silny, “Diagnostics in mycosis fungoides and Sezary syndrome,” Reports of Practical Oncology & Radiotherapy, vol. 19, no. 2, pp. 72–76, 2014.
[2] D. K. Parida and G. K. Rath, “Advantages and implications of high dose rate (HDR) total skin electron irradiation (TSEI) for the management of Mycosis Fungoides. Indian experience,” Reports of Practical Oncology & Radiotherapy, vol. 19, no. 2, pp. 104–108, 2014.
[3] B. J. King, S. C. Lester, S. N. Tolkachjov, M. D. P. Davis, L. E. Gibson, and J. A. Martenson, “Skin-directed radiation therapy for cutaneous lymphoma: the mayo clinic experience,” Journal of the American Academy of Dermatology, vol. 82, no. 3, pp. 634–641, 2020.
[4] M. D. Evans, C. Hudon, E. B. Podgorsak, and C. R. Freeman, “Institutional experience with a rotational total skin electron irradiation (RTSEI) technique—a three decade review (1981–2012),” Reports of Practical Oncology & Radiotherapy, vol. 19, no. 2, pp. 120–134, 2014.
[5] F. W. Hensley, G. Major, C. Edel, H. Hauswald, and M. Bischof, “Technical and dosimetric aspects of the total skin electron beam technique implemented at Heidelberg University Hospital,” Reports of Practical Oncology & Radiotherapy, vol. 19, no. 2, pp. 135–143, 2014.
[6] F. Y. Moraes, A. Carvalho Hde, S. A. Hanna, J. L. F. Da Silva, and G. N. Marta, “Literature review of clinical results of total skin electron irradiation (TSEBT) of mycosis fungoides in adults,” Reports of Practical Oncology & Radiotherapy, vol. 19, no. 2, pp. 92–98, 2014.
[7] https://www.nccn.orgprofessionalsphysician_gls/default.aspx.
[8] J. Kazmierska, “Clinical results of the total skin electron irradiation of the mycosis fungoides in adults. Conventional fractionation and low dose schemes,” Reports of Practical Oncology & Radiotherapy, vol. 19, no. 2, pp. 99–103, 2013.
[9] M. R. Kamstrup, L. Specht, G. L. Skovgaard, and R. Gniadecki, “A prospective, open-label study of low-dose total skin electron beam therapy in mycosis fungoides,” International Journal of Radiation Oncology Biology Physics, vol. 71, no. 4, pp. 1204–1207, 2008.
[10] A. Funk, F. Hensley, and R. Krempien, “Palliative total skin electron beam therapy (TSEBT) for advanced cutaneous T-celllymphoma,” European Journal of Dermatology, vol. 18, no. 3, pp. 308–312, 2008.
[11] P. Maignon, P. Truc, G. Dalac et al., “Radiotherapy of advancedmycosis fungoides: indications and results of total skin electron beam and photon beam irradiation,” Radiotherapy and Oncology, vol. 54, no. 1, pp. 73–78, 2000.
[12] N. Eros, M. Marschalko, A. Bajcsay, C. Polgár, J. Fodor, and S. Kárpáti, “Transient leukonychia after total skin electron beam irradiation,” Journal of the European Academy of Dermatology and Venereology, vol. 25, no. 1, pp. 115–117, 2011.
[13] M. Chowdhary, A. Song, N. G. Zaorsky, and W. Shi, “Total skin electron beam therapy in mycosis fungoides—a shift towards lower dose?” Chinese Clinical Oncology, vol. 8, no. 1, p. 9, 2019.
[14] I. Georgakopoulos, E. Papadavid, K. Platoni et al., “Clinical application of total skin electron beam (TSEB) therapy for the
management of T cell cutaneous lymphomas. The evolving role of low dose (12 Gy) treatment schedule,” *Clinical and Translational Radiation Oncology*, vol. 15, pp. 26–30, 2018.

[15] A. Taverniers, A. Du-Thanh, M. Charissoux, C. Kerr, and O. Dereure, “Low-vs. middle-dose total skin electron beam therapy for mycosis fungoides: an efficiency-based retrospective survey of skin response,” *Acta Dermato Venereologica*, vol. 99, no. 6, pp. 544–550, 2019.

[16] K. Kroeger, K. Elsayad, C. Moustakis, U. Haverkamp, and H. T. Eich, “Low-dose total skin electron beam therapy for cutaneous lymphoma,” *Strahlentherapie und Onkologie*, vol. 193, no. 12, pp. 1024–1030, 2017.

[17] K. Elsayad, K. Kroeger, B. Greve et al., “Low-dose total skin electron beam therapy: quality of life improvement and clinical impact of maintenance and adjuvant treatment in patients with mycosis fungoides or Sezary syndrome,” *Strahlentherapie und Onkologie*, vol. 196, no. 1, pp. 77–84, 2020.

[18] A. Song, A. Gochoco, T Zhan et al., “A prospective cohort study of condensed low dose total skin electron beam therapy for mycosis fungoides: reduction of disease burden and improvement in quality of life,” *Journal of the American Academy of Dermatology*, pp. 30130–30134, 2020.

[19] J. A. Miccio, L. D. Wilson, B. H. Kann et al., “Cutaneous T-cell lymphoma: trends in radiation doses and patterns of care 2004–2015,” *Anticancer Research*, vol. 39, no. 1, pp. 253–259, 2019.

[20] T. O. Thomas, P. Agrawal, J. Guitart et al., “Outcome of patients treated with a single-fraction dose of palliative radiation for cutaneous T-cell lymphoma,” *International Journal of Radiation Oncology Biology Physics*, vol. 85, no. 3, pp. 747–753, 2013.

[21] K. J. Neelis, E. C. Schimmel, M. H. Vermeer, N. J. Senff, R. Willemze, and E. M. Noordijk, “Low-dose palliative radiotherapy for cutaneous B-and T-cell lymphomas,” *International Journal of Radiation Oncology Biology Physics*, vol. 74, no. 1, pp. 154–158, 2009.

[22] https://clinicaltrials.gov/ct2/show/NCT03398161.

[23] L. M. Lindahl, M. R. Kamstrup, P. M. Petersen et al., “Total skin electron beam therapy for cutaneous T-cell lymphoma: a nationwide cohort study from Denmark,” *Acta Oncologica*, vol. 50, no. 8, pp. 1199–1205, 2011.